Sunday 06 Jul, 2025 04:38 AM
Site map | Locate Us | Login
   Rajshree Polypack bags Rs 3-cr supply order    Power and Instrumentation secures Rs 3-cr work order from Nyati Engineering & Construction    RVNL bags Rs 143 cr LoA from Southern Railway for traction system upgrade in Tamil Nadu    Dhanlaxmi Bank gross advances rises 17% YoY in Q1 FY26    Texmaco Rail secures Rs 36-cr wagon order from TCI    Hazoor Multi Projects bags Rs 913-cr solar order from Apollo Green Energy    BEML secures $6.23 million export orders    Shakti Pumps raises Rs 292.6 crore via QIP; PineBridge, LIC MF among top investors    Bank of Maharashtra's total deposits climb 14% YoY to Rs 3.05 lakh crore in Q1    GPT Infraprojects bags supply contract from Bangladesh-based Standard Engineers    Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States    India Ratings affirms ratings of Polyplex Corporation with 'stable' outlook    Nuvama Wealth Management Ltd leads losers in 'A' group    Crisil Ratings reaffirms ratings of GIC Housing Finance at 'AA+/A1+' with 'stable' outlook    Dreamfolks Services Ltd leads losers in 'B' group 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Lupin gains after Nagpur facility receives EIR
18-Oct-19   14:52 Hrs IST

Lupin announced the receipt of the establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for its Nagpur facility. The facility was inspected by the USFDA between 5 and 8 August 2019. The inspection for the oral solid facility at Nagpur closed without any Form 483 observation.

The Nagpur facility is Lupin's largest and most advanced oral solid dosage facility and has maintained a solid track record of compliance.

Commenting on the receipt of the EIR, Nilesh Gupta, managing director, Lupin said, Excelling at quality and compliance is one of our top priorities and we remain committed to meeting and exceeding standards set by regulatory agencies globally.

Meanwhile, the S&P BSE Sensex was up 646 points or 1.72% to 38,177.95. The Nifty Pharma Index was trading 1.03% higher at 7,611.40.

On the BSE, 44,098 shares were traded in the counter so far compared with average daily volumes of 64,929 shares in the past two weeks. The stock hit a high of Rs 746 and a low of Rs 723.05 so far during the day.

The stock hit a 52-week high of Rs 914 on 31 October 2018 and a 52-week low of Rs 646.2 on 7 October 2019.

Lupin's consolidated net profit jumped 49.5% to Rs 303.05 crore on a 15.4% surge in net sales to Rs 4,355.83 crore in Q1 June 2019 compared with Q1 June 2018.

Lupin is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 42445122
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited